Sakar Healthcare

Sakar Healthcare EBIT

The EBIT of Sakar Healthcare (SAKAR.NS) as of Nov 7, 2026 is 453.24 M INR. In the previous year, EBIT was 288.01 M INR — a change of 57.37% (higher).

EBIT

453.24 MINR

YoY

57.37%

Last updated:

In 2026, Sakar Healthcare's EBIT was 453.24 M INR, a 57.37% increase from the 288.01 M INR EBIT recorded in the previous year.

The Sakar Healthcare EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
149.68 M INR
Jan 1, 2022
388.86 M INR
Jan 1, 2023
184.57 M INR
Jan 1, 2024
495.51 M INR
Jan 1, 2025
288.01 M INR
Jan 1, 2026
453.24 M INR
Jan 1, 2027 (e)
740.32 M INR
Jan 1, 2028 (e)
1.25 B INR
The Sakar Healthcare EBIT history
YEAREBITYoY
est1.25 BINR+69.42%
est740.32 MINR+63.34%
453.24 MINR+57.37%
288.01 MINR-41.88%
495.51 MINR+168.46%
184.57 MINR-52.54%
388.86 MINR+159.79%
149.68 MINR+10.03%
136.04 MINR+3.54%
131.40 MINR+59.79%
82.23 MINR-17.25%
99.37 MINR+247.38%
28.61 MINR-46.80%
53.77 MINR-6.11%
57.27 MINR+3.00%
55.60 MINR+6.99%
51.97 MINR+40.35%
37.03 MINR+18.81%
31.17 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sakar Healthcare Revenue

Sakar Healthcare Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
947.39 M INR
149.68 M INR
106.83 M INR
Jan 1, 2022
1.28 B INR
388.86 M INR
152.43 M INR
Jan 1, 2023
1.33 B INR
184.57 M INR
127.59 M INR
Jan 1, 2024
1.54 B INR
495.51 M INR
116.71 M INR
Jan 1, 2025
1.78 B INR
288.01 M INR
175.02 M INR
Jan 1, 2026
2.52 B INR
453.24 M INR
304.85 M INR
Jan 1, 2027 (e)
3.45 B INR
740.32 M INR
511.75 M INR
Jan 1, 2028 (e)
4.81 B INR
1.25 B INR
910.03 M INR

Sakar Healthcare Margins

Sakar Healthcare stock margins

The Sakar Healthcare margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sakar Healthcare. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sakar Healthcare.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
45.65 %
15.80 %
11.28 %
Jan 1, 2022
41.65 %
30.33 %
11.89 %
Jan 1, 2023
44.85 %
13.84 %
9.57 %
Jan 1, 2024
45.38 %
32.14 %
7.57 %
Jan 1, 2025
24.10 %
16.22 %
9.86 %
Jan 1, 2026
26.29 %
18.00 %
12.11 %
Jan 1, 2027 (e)
26.29 %
21.49 %
14.85 %
Jan 1, 2028 (e)
26.29 %
26.09 %
18.93 %

Sakar Healthcare Stock analysis

What does Sakar Healthcare do? Sakar Healthcare Ltd. manufactures pharmaceutical products including liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules and vials, lyophilized injections, and oral solid dosages. The company operates as a contract development and manufacturing organization (CDMO) providing these products under brand names such as Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid, and Lyophilised Injections (In Vials). Sakar Healthcare serves markets in 14 countries including Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, and Cote D’Ivoire with approximately 321 product registrations. The company generates revenue through the sale of these pharmaceutical products to healthcare providers and distributors in these regions. The firm’s manufacturing unit is accredited by regulatory authorities in 14 countries, which enables it to produce and distribute products across these markets. Sakar Healthcare’s product portfolio includes liquid injectables (SVP) in ampoules and vials, dry powder injections, and oral solid dosages, which are sold to healthcare facilities and pharmacies. The company’s contracts with clients in the pharmaceutical sector involve developing and manufacturing products according to their specifications, with the firm’s focus on cephalosporin-based medications and liquid formulations. Sakar Healthcare Ltd. focuses on providing contract manufacturing services for pharmaceutical products, with a strong emphasis on cephalosporin formulations and liquid-based medications. The company’s products are registered in 321 product registrations across various countries, supporting its operations in 14 regulatory markets. Revenue is derived from the production and sale of these registered products to healthcare providers and distributors in the regions where it holds regulatory accreditation. Sakar Healthcare is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Sakar Healthcare's EBIT

Sakar Healthcare's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sakar Healthcare's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sakar Healthcare's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sakar Healthcare’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sakar Healthcare stock

EBIT of Sakar Healthcare is 453.24 M INR in 2026.

EBIT of Sakar Healthcare changed from 288.01 M INR to 453.24 M INR, representing a 57.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Sakar Healthcare since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Sakar Healthcare historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sakar Healthcare

All Key Metrics — Sakar Healthcare